FPMIOTCinactive

FLUOROPHARMA MEDICAL, INC.

Healthcare·Metabolic·Phase 2·Montclair, NJ, United States
Metabolic

FLUOROPHARMA MEDICAL, INC. (FPMI): 2 pipeline candidates · ~1 mo cash runway. Updated within the last hour.

5.2/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.2

0.8 months

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for FLUOROPHARMA MEDICAL, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$7K

Cash

$25K

Quarterly Burn

$116K

Runway

0.8 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (2 candidates)

·CEO: Thomas H. Tulip, Ph.D.

Frequently asked questions

How many drug candidates are in FLUOROPHARMA MEDICAL, INC.'s pipeline?

FLUOROPHARMA MEDICAL, INC. (FPMI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is FLUOROPHARMA MEDICAL, INC.'s lead drug candidate?

FLUOROPHARMA MEDICAL, INC.'s most advanced tracked candidate is bfpet (Phase 2) for Stress-testing for patients with presumptive or proven CAD.

What is FLUOROPHARMA MEDICAL, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, FLUOROPHARMA MEDICAL, INC. has approximately 0.8 months of cash runway.

What is FLUOROPHARMA MEDICAL, INC.'s market capitalization?

FLUOROPHARMA MEDICAL, INC.'s market capitalization is approximately $7K.

Who is the CEO of FLUOROPHARMA MEDICAL, INC.?

Thomas H. Tulip, Ph.D. is the chief executive officer of FLUOROPHARMA MEDICAL, INC. (FPMI).

Get the full picture on FLUOROPHARMA MEDICAL, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.